MYC and lymphoma: Because PLK1 has been implicated in molecular cross talk with MYC [48] and volasertib possibly has an inhibitory activity on the BRD4 protein [26], it is plausible that therapeutic targeting of PLK1 in combination with JQ1 might yield a more favorable therapeutic index in MYC-associated lymphomas.